The Prostate

Funding information Natural Science Foundation of Shanghai, Grant/Award Number: 18ZR1429800; Shanghai Rising‐Star Program, Grant/Award Number: 17QA1403700; The Fifth People`s Hospital of Shanghai, Fudan University, Grant/ Award Number: 2018WYZD02 Abstract Background: POH1, a member of the JAMM domain containing deubiquitinases, functions in malignant progression of certain types of cancer. However, the role of POH1 in prostate cancer (PCa) remains unclear. Methods: We performed RNA interference against the JAMM members in PC3 cells and analyzed cell proliferation. POH1 knockdown was established to evaluate the effects of POH1 on cell growth in vitro and in vivo. RNA‐sequencing was utilized to explore the molecular details underlying the biological function of POH1 in PCa. The expression of POH1 in PCa tissues was detected by immunohistochemistry. The POH1 inhibitor capzimin was evaluated to explore whether pharmacologically inhibiting POH1 significantly affected PCa cell proliferation alone or enhanced the inhibitory efficacy of docetaxel and androgen deprivation. Results: Functional analyses identified POH1 as a JAMM deubiquitinase that is required for PCa proliferation. Importantly, expression of POH1 was higher in human PCa tissues (PCas) than that in normal prostate tissues, and a positive correlation was detected between elevated POH1 expression and higher pathological grades in PCas. In vivo experiments further demonstrated that depleting POH1 significantly suppressed the growth of PCa cell xenografts. POH1 deficiency profoundly inhibited the expression of a set of genes involving the cell cycle and caused G0/G1 phase arrest. Furthermore, the POH1 inhibitor capzimin phenotypically recapitulated the effects of POH1 knockdown and improved the efficacy of docetaxel and androgen deprivation in PCa cells. Conclusions: POH1 was overexpressed in PCas and was correlated with pathological grades in human PCas. Inhibiting POH1 by gene silencing or pharmacological inhibition with capzimin suppressed PCa cell growth. Exploring the inhibition of

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  Zhihua Liu,et al.  Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma. , 2018, Cancer letters.

[3]  J. Yun,et al.  POH1 Knockdown Induces Cancer Cell Apoptosis via p53 and Bim , 2018, Neoplasia.

[4]  J. Qi,et al.  Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance , 2017, Oncogene.

[5]  Seth M. Cohen,et al.  Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. , 2017, Nature chemical biology.

[6]  Q. Xia,et al.  POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation , 2015, Nature Communications.

[7]  R. Dhir,et al.  Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells. , 2015, Molecular endocrinology.

[8]  T. Yao,et al.  Chaperone-mediated 26S Proteasome Remodeling Facilitates Free K63 Ubiquitin Chain Production and Aggresome Clearance* , 2015, The Journal of Biological Chemistry.

[9]  S. Xia,et al.  KLF9, a transcription factor induced in flutamide‐caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells , 2014, The Prostate.

[10]  Meenakshi Bhansali,et al.  COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. , 2014, Molecular endocrinology.

[11]  M. Gleave,et al.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer , 2014, Proceedings of the National Academy of Sciences.

[12]  C. Robson,et al.  Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor* , 2013, The Journal of Biological Chemistry.

[13]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[14]  K. Hochedlinger,et al.  Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. , 2012, Cell stem cell.

[15]  Joanna R. Morris.  Attenuation of the ubiquitin conjugate DNA damage signal by the proteasomal DUB POH1 , 2012, Cell cycle.

[16]  F. Festy,et al.  The proteasomal de‐ubiquitinating enzyme POH1 promotes the double‐strand DNA break response , 2012, The EMBO journal.

[17]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[18]  M. Loda,et al.  MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. , 2012, Cancer discovery.

[19]  R. Bernards,et al.  The Deubiquitinating Enzyme USP26 Is a Regulator of Androgen Receptor Signaling , 2010, Molecular Cancer Research.

[20]  E. Jensen,et al.  The 19S proteasomal lid subunit POH1 enhances the transcriptional activation by Mitf in osteoclasts , 2010, Journal of cellular biochemistry.

[21]  K. Klinger,et al.  Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. , 2010, Experimental cell research.

[22]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[23]  Han Liu,et al.  Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1 , 2009, PloS one.

[24]  J. Hershey,et al.  An Oncogenic Role for the Phosphorylated h-Subunit of Human Translation Initiation Factor eIF3* , 2008, Journal of Biological Chemistry.

[25]  Pier Paolo Pandolfi,et al.  The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network , 2008, Nature.

[26]  C. Glass,et al.  A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. , 2007, Molecular cell.

[27]  M. Rolfe,et al.  The JAMM motif of human deubiquitinase Poh1 is essential for cell viability , 2007, Molecular Cancer Therapeutics.

[28]  P. Ribeiro,et al.  The 19 S Proteasomal Subunit POH1 Contributes to the Regulation of c-Jun Ubiquitination, Stability, and Subcellular Localization* , 2006, Journal of Biological Chemistry.

[29]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[30]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[31]  M. Loda,et al.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. , 2004, Cancer cell.

[32]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[33]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[34]  T. Visakorpi,et al.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. , 2014, Cancer research.

[35]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.